Lansoprazole. - CAS 103577-45-3
Catalog number: 103577-45-3
Category: Inhibitor
Please be kindly noted products are not for therapeutic use. We do not sell to patients.
Molecular Formula:
C16H14F3N3O2S
Molecular Weight:
369.3615
COA:
Inquire
Targets:
Proton Pump
Description:
Lansoprazole is a proton-pump inhibitor (PPI) which prevents the stomach from producing gastric acid.
Synonyms:
Lansoprazole
MSDS:
Inquire
InChIKey:
MJIHNNLFOKEZEW-UHFFFAOYSA-N
InChI:
InChI=1S/C16H14F3N3O2S/c1-10-13(20-7-6-14(10)24-9-16(17,18)19)8-25(23)15-21-11-4-2-3-5-12(11)22-15/h2-7H,8-9H2,1H3,(H,21,22)
Canonical SMILES:
CC1=C(C=CN=C1CS(=O)C2=NC3=CC=CC=C3N2)OCC(F)(F)F
Current Developer:
Apricus Biosciences (developing it as anticancer agent)
1.Lansoprazole and carbonic anhydrase IX inhibitors sinergize against human melanoma cells.
Federici C1, Lugini L1, Marino ML1, Carta F2, Iessi E1, Azzarito T1, Supuran CT2, Fais S1. J Enzyme Inhib Med Chem. 2016 May 3:1-7. [Epub ahead of print]
CONTEXT: Proton Pump Inhibitors (PPIs) reduce tumor acidity and therefore resistance of tumors to drugs. Carbonic Anhydrase IX (CA IX) inhibitors have proven to be effective against tumors, while tumor acidity might impair their full effectiveness.
2.A 12-month follow-up study on the preventive effect of oral lansoprazole on acute exacerbation of chronic obstructive pulmonary disease.
Xiong W1, Zhang QS2, Zhao W3, Ding W4, Liu JM5, Zhao YF6. Int J Exp Pathol. 2016 May 2. doi: 10.1111/iep.12173. [Epub ahead of print]
The objective of this study was to evaluate the preventive effects of oral administration of lansoprazole on acute exacerbation of chronic obstructive pulmonary disease (COPD). Patients with COPD in groups C and D in the stable phase were stratified into a group with neither gastroesophageal reflux nor lansoprazole therapy (group A) and a group subjected to oral lansoprazole therapy (group B1 ) and a group not subjected to oral lansoprazole therapy (group B2 ). The frequency scale for the symptoms of gastroesophageal reflux disease (FSSG) questionnaire, COPD assessment test (CAT) questionnaire, pulmonary function test and the 6-minute walk test were applied; in addition, arterial blood gas, white blood cell (WBC), hs-CRP, liver function and the levels of IL-1β, IL-6, IL-8, TNF-α and GM-CSF in sputum were monitored during follow-up. In the 12-month follow-up period, the frequency of exacerbation in group B2 was statistically higher than that in groups A and B1 (P < 0.
3.Lansoprazole and carbonic anhydrase IX inhibitors sinergize against human melanoma cells.
Federici C1, Lugini L1, Marino ML1, Carta F2, Iessi E1, Azzarito T1, Supuran CT2, Fais S1. J Enzyme Inhib Med Chem. 2016 May 3:1-7. [Epub ahead of print]
CONTEXT: Proton Pump Inhibitors (PPIs) reduce tumor acidity and therefore resistance of tumors to drugs. Carbonic Anhydrase IX (CA IX) inhibitors have proven to be effective against tumors, while tumor acidity might impair their full effectiveness.
4.A 12-month follow-up study on the preventive effect of oral lansoprazole on acute exacerbation of chronic obstructive pulmonary disease.
Xiong W1, Zhang QS2, Zhao W3, Ding W4, Liu JM5, Zhao YF6. Int J Exp Pathol. 2016 May 2. doi: 10.1111/iep.12173. [Epub ahead of print]
The objective of this study was to evaluate the preventive effects of oral administration of lansoprazole on acute exacerbation of chronic obstructive pulmonary disease (COPD). Patients with COPD in groups C and D in the stable phase were stratified into a group with neither gastroesophageal reflux nor lansoprazole therapy (group A) and a group subjected to oral lansoprazole therapy (group B1 ) and a group not subjected to oral lansoprazole therapy (group B2 ). The frequency scale for the symptoms of gastroesophageal reflux disease (FSSG) questionnaire, COPD assessment test (CAT) questionnaire, pulmonary function test and the 6-minute walk test were applied; in addition, arterial blood gas, white blood cell (WBC), hs-CRP, liver function and the levels of IL-1β, IL-6, IL-8, TNF-α and GM-CSF in sputum were monitored during follow-up. In the 12-month follow-up period, the frequency of exacerbation in group B2 was statistically higher than that in groups A and B1 (P < 0.
Molecular Weight Calculator Molarity Calculator Solution Dilution Calculator

Related Proton Pump Products


CAS 117976-90-6 Rabeprazole Sodium

Rabeprazole Sodium
(CAS: 117976-90-6)

The sodium salt form of Rabeprazole which is a partially reversible inhibitor of gastric proton pump and could be used in the treatment of sorts of gastrointest...

CAS 135779-82-7 Bamaquimast

Bamaquimast
(CAS: 135779-82-7)

Bamaquimast is an orally active inhibitor of proton pump with anti-inflammatory and antiasthmatic effects.

CAS 138786-67-1 Pantoprazole sodium

Pantoprazole sodium
(CAS: 138786-67-1)

The sodium salt form of Pantoprazole, a gastic proton pump inhibitor, could be used in the treatment of ulceration and some diseases induced by gastroesophageal...

CAS 73590-58-6 Omeprazole

Omeprazole
(CAS: 73590-58-6)

Omeprazole is a proton pump inhibitor used in the treatment of dyspepsia. It binds to the proton pump hydrogen-potassium adenosine triphosphatase (H+/K+ ATPase)...

Lansoprazole sodium
(CAS: 226904-00-3)

Lansoprazole sodium is the sodium salt form of Lansoprazole. Lansoprazole, a substituted benzimidizole, is proton pump inhibitor, is a proton pump inhibitor whi...

CAS 161796-84-5 Esomeprazole potassium

Esomeprazole potassium
(CAS: 161796-84-5)

Esomeprazole potassium is a proton pump inhibitor which acts as selective inhibiton of H+/K+-ATPase. With antiulcerative effects in vivo, it treats or ameliorat...

CAS 261944-46-1 Soraprazan

Soraprazan
(CAS: 261944-46-1)

Soraprazan, also known as BY359, is a reversible, and fast-acting inhibitor of gastric H+/K+ ATPase, used as anti-secretory drug.

CAS 103577-45-3 Lansoprazole.

Lansoprazole.
(CAS: 103577-45-3)

Lansoprazole is a proton-pump inhibitor (PPI) which prevents the stomach from producing gastric acid.

Chemical Structure

CAS 103577-45-3 Lansoprazole.

Quick Inquiry

Verification code

Featured Items